SP2086 + valsartan

SP2086 + valsartan is a **combination investigational drug**, consisting of SP2086 (retagliptin phosphate) and valsartan. SP2086 (retagliptin phosphate) is a **selective and orally active dipeptidyl peptidase-4 (DPP-4) inhibitor**, developed for the treatment of type 2 diabetes mellitus. It enhances incretin activity by inhibiting the DPP-4 enzyme, thereby increasing insulin secretion and decreasing glucagon release in a glucose-dependent manner[1][3][7]. Valsartan is an angiotensin II receptor blocker (ARB) used primarily for hypertension and heart failure. The combination is likely intended for patients with both type 2 diabetes and cardiovascular risk or comorbidity, but there is currently **no evidence of clinical trials or regulatory approval specifically for the SP2086 + valsartan combination**. Most available research and clinical studies focus on SP2086 alone or in combination with metformin, not valsartan[2][3][8]. Therefore, details on efficacy, safety, and regulatory status for this combination are lacking.